Ate-Bev Early Response Prediction Model in Advanced HCC
The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the
| Condition(s) | Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage. |
| Who can participate | Inclusion Criteria: * Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy * Patients willing to participate in this study Exclusion Criteria: * Individuals with a history of severe contrast allergy * Individuals with severe comorbidities (according to the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction.) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Seoul National University Hospital |
| Locations | Seoul, South Korea |
| Start date | 2022-07-22 |
| NCT ID | NCT05763277 |
| Official listing | https://clinicaltrials.gov/study/NCT05763277 |